Since the 19th century, arsenic (As 2 O 3 ) has been used in the treatment of chronic myelogenous leukemia (CML) characterized by the t(9;22) translocation. As 2 O 3 induces complete remissions in patients with acute promyelocytic leukemia. The response to As 2 O 3 is genetically determined by the t(15;17)-or the t(9;22)-specific fusion proteins PML/RARa or BCR/ABL. The PML portion of PML/RARa is crucial for the sensitivity to As 2 O 3 . PML is nearly entirely contained in PML/RARa. PML is upregulated by oncogenic RAS in primary fibroblasts. The aberrant kinase activity of BCR/ABL leads to constitutive activation of RAS. Therefore, we hypothesized that BCR/ ABL could increase sensitivity to As 2 O 2 -induced apoptosis by modifying PML expression. To disclose the mechanism of As 2 O 3 -induced apoptosis in PML/RARaand BCR/ABL-expressing cells, we focused on the role of PML for As 2 O 3 -induced cell death. Here we report that (i) sensitivity to As 2 O 3 -induced apoptosis of U937 cells can be increased either by overexpression of PML, or by conditional expression of activated RAS; (ii) also the expression of the t(8;21)-related AML-1/ETO increased sensitivity to As 2 O 3 -induced apoptosis; (iii) both BCR/ ABL and AML-1/ETO activated RAS and modified the PML expression pattern; (iv) the expression of either BCR/ABL or AML-1/ETO rendered U937 cells sensitive to interferon a-induced apoptosis. In summary, these data suggest a crucial role of factors able to upregulate PML for As 2 O 2 -induced cell death.
Introduction
The recent history of the use of trivalent arsenic as a therapeutic agent coincides with the history of treatment of chronic myelogenous leukemia (CML). The modern chemotherapeutic era for leukemia began in 1865 with case reports by two German physicians who used Fowler's solution for the treatment of leukemia (Lissauer, 1865; Valentiner, 1865 ). Fowler's solution for the treatment of CML was 'rediscovered' in 1931 when it was used in a study with 10 patients suffering from advanced CML. Nine of 10 patients showed a good clinical response to this treatment (Forkner and Scott, 1931) . This study contributed to the establishment of arsenic as a part of standard treatment of CML until the 50s of the past century (Sears, 1988) .
The renaissance of arsenic in the 90s of the past century was due to the observation that trivalent arsenic trioxide (As 2 O 3 ) is effective in the treatment of acute promyelocytic leukemia (APL). APL is characterized by the t(15;17) encoding for the translocation product PML/RARa. We have recently shown that the response of APL cells to As 2 O 3 -induced apoptosis is genetically determined by the presence of t(15;17) and the expression of the related translocation product PML/RARa (Sternsdorf et al., 1999) . T(11;17)-positive APL patients, whose blasts express another APL-specific translocation product, PLZF/RARa, are resistant to As 2 O 3 treatment (Koken et al., 1999) . In contrast to PML/RARa, PLZF/ RARa is unable to mediate As 2 O 3 -induced apoptosis (Sternsdorf et al., 1999) .
Blasts of patients suffering from CML present, in more than 95% of cases, the Philadelphia chromosome (Ph þ ), the morphological substrate of t(9;22). The t(9;22)-related translocation products are the BCR/ABL fusion proteins. The fusion of BCR to ABL leads to constitutive autophosphorylation of ABL, whose physiological counterpart is finely regulated by a variety of stimuli. Constitutively activated ABL induces aberrant proliferation and neoplastic transformation by constitutive activation of RAS (Faderl et al., 1999) .
A constitutively activated RAS, such as the oncogenic V12RAS, provokes a senescent-like arrest in diploid fibroblasts involving the Rb and p53 tumor suppressor pathways (Ferbeyre et al., 2000; Pearson et al., 2000) . One of the genes upregulated during RAS-induced arrest was PML (Ferbeyre et al., 2000) .
PML is localized to specific nuclear matrix-associated subdomains referred to as PML nuclear bodies (PML-NB). These structures can be visualized by immunostaining as specific 'speckles'. In PML/RARa-expressing cells, PML-NBs are disrupted into a finely granular, socalled 'microspeckled' immunostaining pattern (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) . Exposure to drugs able to induce complete remission from APL such as all-trans retinoic acid (t-RA) as well as As 2 O 3 results in a redistribution of the microspeckled pattern and a reconstitution of the normal PML-NB pattern (Weis et al., 1994; Zhu et al., 1997) .
Several factors are able to influence the subnuclear organization of PML-NBs such as As 2 O 3 , interferon a (Infa) and g (Infg) , the expression of oncogenic/activated RAS (Ferbeyre et al., 2000) as well as the expression of the AML-associated translocation product AML-1/ETO (McNeil et al., 2000) .
Induction of senescence by RAS and PML, respectively, is p53 dependent (Ferbeyre et al., 2000; Pearson et al., 2000) . PML seems to regulate p53 function in an isoform-specific manner (Fogal et al., 2000) by regulating its acetylation (Pearson et al., 2000) as well as its serine-phosphorylation (Ferbeyre et al., 2000) . The expression of RAS induces relocalization of p53 within the PML-NBs and RAS-induced p53-acetylation and the resulting senescence is eliminated in PMLÀ/À fibroblasts.
We hypothesized that PML could be the common factor rendering blasts of two completely different subtypes of leukemia, the Ph þ CML and the t(15;17)-positive APL, responsive to As 2 O 3 treatment. Therefore, we investigated the effect of PML and several factors able to modify its expression on the response to As 2 O 3 -induced apoptosis.
Results
Overexpression of PML IV as well as PML III increases the sensitivity to As 2 O 3 -induced apoptosis
In normal cells As 2 O 3 targets mainly PML, and in APLblasts the PML portion of PML/RARa (Sternsdorf et al., 1999) . Furthermore, PML is involved in several signaling pathways of apoptosis (Quignon et al., 1998; Wang et al., 1998) . These facts prompted us to investigate the role of PML in As 2 O 3 -induced apoptosis. Thus, we transfected the PML IV encoding cDNA under the control of the Zn 2 þ -inducible MT-1 promoter by electroporation into U937 cells and selected PML IV overexpressing U937 cells (see Material and methods). Figure 1a depicts the Zn 2 þ -inducible expression of PML IV overexpressing U937 cells used in this study in comparison to the PML/RARa-expressing U937 cells (Grignani et al., 1993) . Apoptosis was measured following 72-96 h of As 2 O 3 exposure by FACSscan analysis of cells stained with 7-AAD as described previously (Sternsdorf et al., 1999; Puccetti et al., 2000) . As 2 O 3 induced cell death in PML IV-positive as well as in PML/RARa-positive U937 cells, when transgene expression was induced by Zn 2 þ treatment (ca. 80 and 95%, respectively). No effect was seen on mock-transfected (MT) control cells in the presence as well as in the absence of Zn 2 þ (Figure 1a) . The low rate of apoptosis induced by As 2 O 3 in PML/RARa as well as in PML IV transfected cells in the absence of Zn 2 þ (ca. 20 and 33%, respectively) ( Figure 1a ) was most likely due to a slight 'leakage' expression from the MT-1 promoter of the transgenes, which was not detectable by Western blot analysis. The a variant lacking exon 5 of PML IV as well as of PML III (Jensen et al., 2001 ) also increased the sensitivity of U937 cells to As 2 O 3 -induced apoptosis (data not shown).
PML IV is the specific PML isoform with prosenescent activity involving p53 activation (Bischof et al., 2002) . Therefore, we investigated whether the overexpression of another PML isoform, PML III, is able to increase the sensitivity of U937 for As 2 O 3 -induced apoptosis. Therefore, we created U937 cells expressing PML III under control of the Zn 2 þ -inducible MT-1 promoter as described above. In the absence and presence of Zn 2 þ -induction of the transgene, the exposure to As 2 O 3 induced cell death in PML III-positive U937 cells (ca. 35%). The high rate of As 2 O 3 -induced apoptosis in the absence of Zn 2 þ was most likely due to 'leakage' expression from the MT-1 promoter as seen in the Western blot (Figure 1b) . These data suggest that modification of the expression level of PML IV as well as of PML III sensitizes U937 cells to As 2 O 3 -induced apoptosis.
In pre-B lymphoblasts expression of BCR/ABL alters the PML-immunostaining pattern
We have recently shown that the expression of BCR/ ABL renders cells sensitive to As 2 O 3 -induced cell death. Oncogenic/activated RAS upregulates PML in untransformed cells (Ferbeyre et al., 2000) . The fact that BCR/ ABL activates RAS (Faderl et al., 1999) prompted us to study the influence of BCR/ABL on the expression of PML and its significance for the As 2 O 3 -induced cell death. Thus, we investigated the influence of the expression of BCR/ABL on PML in Ph þ lymphoblasts. PML expression was assessed by confocal immunofluorescence microscopy in two BCR/ABLexpressing cell lines, BV173 and Sup B15, in comparison to the BCR/ABL-negative Nalm-6 cells. All are pre-B lymphoblastic cells with a comparable stage of differentiation. As shown in Figure 2a , Nalm-6 cells exhibited two types of cells with respect to the PML-staining pattern, one with only 3-4 nuclear dots with one more pronounced dot per cell and another with 10-30 smaller nuclear dots per cell. The PML-staining pattern of BCR/ABL-expressing BV173 cells is characterized by a higher number of nuclear dots (15-30) with a great majority of large dots as compared to that seen in the Nalm-6 cells ( Figure 2a) . BCR/ABL-expressing SupB15 exhibited a particular PML-staining pattern characterized by a few very large dots as compared to Nalm-6 cells. To prove that the PML-staining pattern of SupB15 is directly related to the presence of BCR/ABL, SupB15 were exposed to the ABL-specific kinase inhibitor STI571. STI571 is able to interrupt the transforming signaling cascade initiated by BCR/ABL, which involves activated RAS. The inhibition of the BCR/ABL kinase activity in SupB15 cells upon exposure to 2 mm of STI571, strongly reduced the size and number of the PML-signals (Figure 2a) .
To confirm the influence of BCR/ABL expression on PML expression, we exposed blasts from three patients with Ph þ acute lymphatic leukemia (ALL) to STI571. One of these patients (patient 1) had a low tumor load (o10% of blast in the bone marrow) and was employed as a negative control, whereas two (patient 2 and 3) presented a high tumor load (between 50 and 70%) (data not shown). The inhibition of the BCR/ABL kinase activity by STI571 decreased the PML expression in the patients with high tumor load, where the BCR/ ABL-expressing leukemic blasts present the majority of the cell population ( Figure 2b ).
Taken together, these data provide first evidence of the fact that the presence of active BCR/ABL influences the PML expression level and PML-NB morphology.
Expression of BCR/ABL leads to modification of PML-NB morphology in U937 cells
To further clearify whether there is a direct relationship between the modification of PML-NBs and the expression of BCR/ABL, we investigated whether the forced expression of BCR/ABL in U937 cells would be able to modify the PML-NBs. As control, we used another leukemia-associated translocation product known to reorganize PML-NBs, the t(8;21)-associated AML-1/ ETO (McNeil et al., 2000) . Thus, we compared the PML-NBs in U937 cells expressing BCR/ABL or AML-1/ETO with that of MT cells. The morphology of the PML-NBs was studied as described above. These cell lines express their transgenes under the control of the Zn 2 þ -inducible MT-1 promoter ( Figure 1b and Materials and methods). As shown in Figure 3a , the (Puccetti et al., 2000) . The Zn 2 þ -induced expression of AML-1/ETO led to enlargement of PML-NBs with respect to untreated cells.
To test whether the modification of the PML-NBs by BCR/ABL and AML-1/ETO is due to the influence of the translocation products on the expression of PML, we investigated the expression level of PML in these cells by Western blot. To confirm the role of PML in As 2 O 3 -induced apoptosis, we extended the study to PLZF/RARa-expressing U937 cells, which are resistant to As 2 O 3 -induced apoptosis, comparable to patients suffering from t(11;17)-positive APL. The induction of the transgenes by exposure to Zn 2 þ led to an increase of the anti-PML signal in BCR/ABL-and AML-1/ ETO-expressing cells, but not in PLZF/RARa-positive U937 cells (Figure 3c ). The leakage from the MT-1 promoter in the BCR/ABL-positive U937 cells was sufficient to increase the expression of PML strongly (Figure 3c ).
These data show that in U937 cells, the expression of BCR/ABL and AML-1/ETO, but not of PLZF/ RARa, alters PML-NBs by increasing the expression of PML.
Like PML/RARa and BCR/ABL, the t(8;21) translocation product AML-1/ETO also mediates As 2 O 3 -induced cell death
To answer the question as to whether the other PML-NB modifying translocation product AML-1/ETO is also able to mediate apoptosis, we exposed Kasumi-1 cells that were derived from a t(8;21)-positive AML patient and express AML-1/ETO to 2 mm As 2 O 3 . As shown in Figure 4 , these cells were highly sensitive to As 2 O 3 -induced apoptosis when compared to U937 control (MT) cells.
To exclude the role of an unknown feature, such as differentiation stage, additional genetic aberrations for As 2 O 3 -sensitivity of Kasumi-1 cells, we analysed the effect of As 2 O 3 on AML-1/ETO-expressing U937 cells. As positive control for responsiveness to As 2 O 3 , we used U937 cells expressing PML/RARa and BCR/ABL. As negative control, we used PLZF/RARa and MT U937 cells as described previously (Sternsdorf et al., 1999; Puccetti et al., 2000) . All these cell lines express their transgenes under the control of an Zn 2 þ -inducible MT-1 promoter. Apoptosis was measured as described above. As 2 O 3 induced cell death only in the presence of Zn 2 þ -induced protein expression in PML/RARa, BCR/ABL as well as in AML-1/ETO-transfected cells, but not in PLZF/RARa or in mock-transfected cells. The death rate in the AML-1/ETO-expressing cells was similar to that seen in BCR/ABL-or PML/RARa-expressing U937 Taken together, these data indicate that AML-1/ ETO, similar to PML/RARa and BCR/ABL, is able to mediate As 2 O 3 -induced apoptosis.
Expression of BCR/ABL as well as of AML-1/ETO leads to activation of endogenous RAS in U937 cells and the expression of V12RAS sensitizes U937 cells to As 2 O 3 -induced apoptosis
The expression of BCR/ABL activates RAS signaling (Faderl et al., 1999) . The fact that activated RAS is able to induce PML expression prompted us to address the question of whether the activation of RAS could play a role in the As 2 O 3 -induced apoptosis. To clear the common signaling pathway by which BCR/ABL and AML-1/ETO modify PML expression, we studied the rate of RAS activation in U937 cells expressing these translocation products in comparison to MT control cells. We investigated the RAS activation by Raf-1 RBD-based 'pull downs' (see Materials and methods). As shown in Figure 5a , we found that in contrast to PML/RARa-expressing cells, the expression of BCR/ ABL as well as of AML-1/ETO led to a high level of activated RAS.
To disclose the effect of RAS activation on the As 2 O 3 sensitivity of U937 cells, we studied the As 2 O 3 sensitivity of U937 cells expressing the constitutively activated RAS mutant V12RAS. Therefore, we transfected the V12Ras cDNA under the control of the Zn 2 þ -inducible MT-1 promoter into U937 cells (see Materials and methods). G418 selection gave V12RAS-positive bulk populations, which were then diluted to clones by limiting dilution. The transgene expression was detected as described above. In Figure 5b , the V12RAS expression levels of two clonal and two bulk populations are reported. Bulks1 and 2 were not selected by limiting dilution and only 10-30% of cells expressed V12RAS as determined by the analysis of clones after limiting dilution (data not shown). Clone 1 exhibited a very high 'leakage' expression from the MT-1 promoter, which was comparable to that induced by the expression of BCR/ABL in U937 cells (data not shown). As shown in Figure 5c , the sensitivity of V12RAS-expressing U937 cells to As 2 O 3 -induced apoptosis was directly related to the V12RAS expression level.
Taken together, these data indicate that activated RAS sensitizes U937 cells to As 2 O 3 -induced apoptosis and that RAS is activated only in U937 cells expressing BCR/ABL as well as AML-1/ETO, but not in PML/ RARa-positive cells.
As 2 O 3 -induced apoptosis can occur in a p53-independent manner PML regulates p53 activity during the process of senescence in primary fibroblasts in an isoform-dependent manner (Fogal et al., 2000; Pearson et al., 2000) . Hence, we studied the role of p53 in As 2 O 3 -induced apoptosis in Ph þ lymphoblastic cells known to be highly sensitive to As 2 O 3 , such as TOM-1, SupB15, and BV173 as well as the myeloid K562 cells (Puccetti et al., 2000) . Therefore, we investigated p53 expression upon induction of apoptosis by the anthracyclin doxorubicin (doxo) in these cells. As shown in Figure 6a , in all cells treated with doxo a normal-sized p53 protein was detected with the exception of K562 and U937 cells, in which no p53 protein was detectable. It is noteworthy, that U937 cells can be rendered As 2 O 3 sensitive by the expression of PML/RARa, BCR/ABL as well as by AML-1/ETO as shown above. To ascertain that As 2 O 3 can induce apoptosis in a p53-independent manner, we studied the effect of As 2 O 3 on the p53 expression level in As 2 O 3 -sensitive cells (BV173 and SupB15) in comparison to As 2 O 3 -resistant cells (Nalm-6). We used doxo-induced p53 upregulation as positive control. As depicted in Figure 6b in contrast to doxo, either after 48 h of exposition, As 2 O 3 did not induce p53 expression in the tested cells, independent of their As 2 O 3 sensitivity.
Taken together, these data indicate that the As 2 O 3 -induced apoptosis can occur independent of upregulation of functional p53.
In contrast to PLZF/RARa, the expression of BCR/ABL as well as of AML-1/ETO increases sensitivity to Infa-induced cell death
The modification of PML-NBs is related to the expression of AML-1/ETO as well as BCR/ABL sensitized cells for As 2 O 3 -induced apoptosis. Another factor that is able to modify PML-expression and PMLNBs are interferons, Infa as well as Infg. Both Infa and Infg activate the PML-promoter . Infa is a highly efficient agent for the treatment of CML. In patients suffering from chronic-phase CML, Infa is able to induce complete cytogenetic remissions. The mechanism by which Infa reduces the number of CML blasts is widely unknown (Faderl et al., 1999) .
To investigate whether the expression of the leukemiaassociated translocation products would also be able to increase the sensitivity of the U937 cells to Infa, we compared the activity of Infa with that of As 2 O 3 .
Therefore, we exposed the control cells (MT), PLZF/ RARa, AML-1/ETO as well as BCR/ABL-expressing U937 cells to 10 and 100 IU/ml of Infa or to 2 mm of As 2 O 3 in the absence and presence of Zn 2 þ -induced protein expression from the transgene. As depicted in Figure 7 , neither 10 nor 100 IU/ml of Infa was able to induce significant cell death in control cells. PLZF/ RARa-expressing U937 cells seemed to be protected from Infa effects. The expression of AML-1/ETO or BCR/ABL, respectively, sensitized the cells to the effects of Infa and the cells reached apoptosis rates comparable to that induced by As 2 O 3 . The effects were already clear at 10 IU/ml of Infa. Very similar data were obtained by treating the cells with Infg (data not shown).
Taken together, these data suggest that the effects of Infa are mediated or blocked by the same translocation products that govern the sensitivity of As 2 O 3 and that Infa-induced cell death may need the mediation of pathways activated by BCR/ABL or AML-1/ETO.
Discussion
In the present work, we provide evidence of the fact that factors able to modify PML expression could be responsible for increased sensitivity to As 2 O 3 -induced cell death. This modification of PML can be either qualitative or quantitative.
Qualitative modification is given in the case of the t(15;17) translocation product PML/RARa, containing a C-terminally truncated PML which has lost its physiological intranuclear localization in the context of (Gianni et al., 1998; Sternsdorf et al., 1999) . This function of PML/RARa is independent from the functionality of its RARa portion, which is indispensable for the other features of APLphenotype such as differentiation block and response to t-RA (Sternsdorf et al., 1999) . The crucial role of the PML-portion of PML/RARa for As 2 O 3 response is also proven by the fact that the other APL-specific t(11;17)-related translocation product PLZF/RARa, containing the identical RARa-portion, is unable to mediate As 2 O 3 -induced apoptosis (Sternsdorf et al., 1999) .
Also, a quantitative modification of PML is able to increase sensitivity to As 2 O 3 -induced apoptosis. In fact, here we report that the overexpression of PML dramatically increased the response to As 2 O 3 in cells otherwise resistant to As 2 O 3 . That PML expression is quantitatively modified by the expression of BCR/ABL is proven by the fact that the inactivation of BCR/ABL kinase activity by the treatment with STI571 led to a reduction of PML expression in SupB15 cells as well as in Ph þ ALL blasts. BCR/ABL-expressing lymphatic cells, such as SupB15 and BV173, exhibit a different PML-immunostaining pattern as compared to the BCR/ ABL-negative Nalm-6 cells, characterized by a higher number as well as by a bigger size of PML-NBs. Furthermore, in contrast to PLZF/RARa, which is unable to increase sensitivity to As 2 O 3 -induced apoptosis, the forced expression of BCR/ABL as well as of AML-1/ETO in U937 cells, known to modify the PMLNBs (McNeil et al., 2000) , led to an increase in the number and size of the PML-NBs as compared to control cells. This is confirmed by a higher expression level of a highly modified form of PML detected in the Western blot analysis.
The influence of activated RAS on the expression of PML could represent the link between the responsiveness to As 2 O 3 of both (BCR/ABL-positive) CML-blasts and (PML/RARa-positive) APL-blasts. PML/RARa sensitizes cells to As 2 O 3 as a PML mutant and BCR/ ABL may upregulate PML by the constitutive activation of RAS. It is known that one of the signaling pathways by which BCR/ABL transforms cells is the constitutive activation of RAS and as shown here BCR/ABL activated RAS in U937 cells as well. Surprisingly, the expression of AML-1/ETO, which is transcription factor, also led to an activation of RAS in U937 cells. The role of RAS activation in the response to As 2 O 3 is proven by the fact that the expression of oncogenic V12RAS rendered U937 cells sensitive to As 2 O 3 -induced apoptosis.
According to previously reported data, the As 2 O 3 function can occur independent of the expression of functional p53 (Chen et al., 2001a, b) . In fact K562, which are reported to be sensitive to As 2 O 3 , are p53 negative (Perkins et al., 2000) . Furthermore, U937 cells that become As 2 O 3 -sensitive when transfected with PML/RARa, BCR/ABL or AML-1/ETO do not express functional p53. Furthermore, exposure to As 2 O 3 does not lead to an upregulation of p53. These findings are corroborated by the fact that PML IV, the PML isoform with specific prosenescent activity involving p53 activation as well as PML III, which does not seem to be related to p53 (Bischof et al., 2002) , increases sensitivity to As 2 O 3 -induced apoptosis. Nevertheless, the involvement of p53 in the As 2 O 3 -induced apoptosis cannot be completely excluded, because (i) the rate of As 2 O 3 -induced apoptosis was higher in the PML IV than in PML III expressing cells and (ii) there were differences of the kinetics by which As 2 O 3 induces apoptosis in p53-negative U937 cells and p53-positive TOM-1, BV173 and SupB15 expressing BCR/ABL. The p53-positive cells undergo apoptosis within 24-36 h, whereas the BCR/ABL-or AML-1/ETO-expressing U937 cells need 72-96 h. If these differences can be attributed to the presence or absence of p53, only those modified by phosphorylation or acetylation remain to be disclosed.
From our data presented here, one could hypothesize that response to As 2 O 3 -induced apoptosis may be the sum of two PML-modifying events. The exposure of cells to As 2 O 3 leads to specific SUMOylation of PML as well as of PML/RARa without influencing SUMOylation status of other proteins such as the nuclear pore component Ran-GAP (Muller et al., 1998; Sternsdorf et al., 1999) . The fact that SUMOylation of PML occurs in each cell exposed to As 2 O 3 , independent of its apoptotic response to As 2 O 3 , indicates that SUMOylation seems to play a role in As 2 O 3 -induced apoptosis only in combination with a second modification. In the case of PML/RARa-positive cells, this is a qualitative modification, meaning the presence of a mutated PML; and in the case of RAS-or BCR/ABL-expressing cells it seems to be a quantitative modification, meaning an upregulation of endogenous PML. This hypothesis is supported by our findings that treatment of cells with Infa, which upregulates PML expression by activating the PML promoter Stadler et al., 1995) , does not induce apoptosis. If Infa upregulates PML expression in cells in which PML is already modified by the expression of AML-1/ETO or BCR/ABL, it induces a high rate of apoptosis. These findings are strongly supported by the effects of Infa on CML-blasts as well as on Ph þ ALL-blasts in vivo, which have been shown to respond to Infa. In fact, Infa is a part of the standard therapy of chronic-phase CML. Its efficacy has also been shown in the treatment of patients suffering from (BCR/ABL) Ph þ ALL (Visani et al., 2000) . Another fact seems to support this hypothesis: infections by virus such as HSV-1, HBV, HCV target PML-NBs as well as PML itself and related diseases often become sensitive to Infa therapy (Lee et al., 1999; Villa et al., 2001) . The entity on which this question was investigated, the HTLV-induced leukemia, has been shown to be sensitive to Infa as well as to As 2 O 3 -therapy (El-Sabban et al., 2000; Mahieux et al., 2001) . This is furthermore supported by preliminary data that show a synergy between As 2 O 3 and INF-a on the colony formation potential of mononuclear cells from six chronic-phase CML patients (Miller et al., 2002) .
In summary, our data presented here provide evidence for the reason why two completely different disease entities such as CML and APL respond to the same apoptosis-inducing agent in a tumor cells specific manner. Furthermore, our results identify other tumor entities expressing activated RAS with concomitant upregulation of PML as potential targets of As 2 O 3 or Infa treatment.
Materials and methods

cDNAs and vectors
XbaI-SpeI digested V12RAS a well as PML IV (kindly provided by Pier Giuseppe Pelicci, JEO, Milan, Italy) and PML III (kindly provided by Hans Will, HPI, Hamburg, Germany) (Jensen et al., 2001 ) fragments were ligated into the pGMTSVneo (Grignani et al., 1993) digested with XbaI. The a forms of PML VI and PML III containing exon 5 were used (Jensen et al., 2001) .
Cell culture, cell lines, protein expression and Western blotting U937, K562, BV173 and Nalm-6 cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and in the case of SupB15 and Kasumi-1, with 20% FCS. TOM-1 was maintained in DMEM with 20% FCS. The U937 expressing PLZF/RARa, PML/RARa, the HA-tagged AML-1/ETO or BCR/ABL under the control of the Zninducible MT-1 promoter were described previously (Grignani et al., 1993; Ruthardt et al., 1997; Puccetti et al., 2000 Puccetti et al., , 2002 . The PML IV-, PML III-, PML and V12RAS-expressing bulk populations were obtained by electroporation of the respective cDNA under the control of the Zn 2 þ -inducible MT-1 promoter into U937 cells as described pre-viously (Ruthardt et al., 1997) . After G418 selection and limiting dilution, bulk populations and clones positive for transgene expression were obtained. Bulk populations and clones were selected for further analysis by two criteria: (i) increased protein expression upon Zn 2 þ treatment and (ii) the capacity of each clone to undergo VitD 3 -induced terminal differentiation in the absence of Zn 2 þ (not shown). Expression of the exogenous protein was induced by treatment for 6-12 h with 100 mm ZnSO 4 (Zn 2 þ ) as described (Ruthardt et al., 1997) . Protein expression was evaluated by Western blotting after 6-12 h of Zn 2 þ treatment using the specific anti-RARa (Sternsdorf et al., 1999) ; and anti-PML (Stuurman et al., 1992) or anti-ABL-antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blocking and antibody incubations were performed in 5% low-fat dry milk, washing was carried out in PBS containing 0.1% Tween 20. Activated RAS was detected by the 'RAS Activation Assay Kit' which is based on a 'pull down' of activated RAS by the RAF1 RAS binding domain fused to GST (RAF1-RBD-GST) according to the manufacturer's instructions (Upstate Biotechnology, Lake Placid, NY, USA).
Patient material and treatment
Mononuclear cells derived from the bone marrow of two patients with newly diagnosed ALL and from one patient with ALL in partial remission with o10% of blasts were isolated by FicollHypaque density-gradient centrifugation and washed twice with PBS. The cells were plated at 10 6 cells/ml in a six-well plate. The cells were incubated for 24 h in the presence and absence of 2 mm of STI571 (Glivec, kindly provided by E Buchdunger, Novartis, Basel, Switzerland) and then lysed in Laemmli buffer for Western analysis following widely established protocols.
Induction of apoptosis and apoptosis assay
For induction of apoptosis, the cells were washed after Zn 2 þ treatment, diluted to a concentration of 1 Â 10 5 cell/ml and exposed to an end concentration of 2 mm As 2 O 3 (Sigma, St Louis, MO, USA) by 1 : 500 dilution of a 1 mm stock solution in phosphate-buffered saline (PBS). For analysis of apoptosis, the FACS-based 7-amino-actinomycin D (7-AAD) method was used as described previously (Sternsdorf et al., 1999; Puccetti et al., 2000) .
Immunofluorescence
Cells were allowed to adhere to poly-d lysine (Sigma, Deisenhofen, Germany)-coated coverslips for 30 min at 41C and fixed in 3.7% paraformaldehyde in CSK (10 mm PIPES, 0.1 m NaCl, 0.3 m sucrose, 3 mm MgCl 2 , 2mm EDTA) for 30 min, permeated with 1% Triton X-100 for 5 min at RT. The monoclonal mouse anti-PML antibody (PGM3, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was diluted 1 : 50 and incubated for at least 1 h, and after washing with PBS, the second antibodies goat anti-mouse Cy2-conjugated (Amersham Biosciences, Freiburg, Germany) (diluted 1 : 100) were incubated for 45 min. Antibody incubations were performed in 1% bovine serum albumin; washing was carried out in PBS. A short wash in H 2 O was carried out before the coverslips were mounted with Moviol (Sigma, Deisenhofen, Germany). Samples were examined using a Leica TCS-NT confocal microscope and images were processed using Leica TCS-NT V1.6.551 (Leica, Wetzlar, Germany) and Imaris 3 (Bitplane, Zu¨rich, Switzerland) software. In a given experiment, pictures of pinehole opening, laser power, photomultiplier tension and layer number were taken under identical conditions for each sample. Also, during data elaboration by Imaris 3 software identical parameters were applied for each sample of a given experiment.
